Irisin and chemerin levels in patients with type 2 diabetes mellitus

Küçük Resim



Dergi Başlığı

Dergi ISSN

Cilt Başlığı


Acta Endocrinologica Foundation

Erişim Hakkı



Context. Changes in the secretion of signaling molecules that originates from adipose tissue and inflammation draw attention in the pathogenesis of type 2 DM. Chemerin, one of the signaling molecules of adipose origin, and irisin, defined as the Renaissance of the metabolism, are among these molecules. Objectives. This cross-sectional study was planned in order to compare the values of serum irisin and chemerin levels in patients newly diagnosed with T2DM and in healthy subjects. Subjects and Methods. The study included 41 patients newly diagnosed with T2DM and 49 healthy individuals. The chemistry parameters were analyzed with a biochemistry autoanalyzer, and hormonal parameters were analyzed with an immunoassay analyzer. Plasma irisin and chemerin levels were measured using the enzyme-linked immunosorbent assay method. Results. There was a significant difference between the groups in terms of glucose, HbA1C, Insulin, HOMA-IR and lipid panel results. Irisin levels in the group of patients newly diagnosed with T2DM were lower than in the control group. Chemerin levels in the group of patients newly diagnosed with T2DM were higher than in the control group. Conclusion. Consequently, diabetes-dependent changes in chemerin and irisin concentrations suggest that these two hormones have a role in the pathophysiology of DM. Further studies are required to understand the complex structure of the signaling pathways of chemerin and irisin molecules as well as the physiological importance of these molecules as metabolism regulators especially in humans. © 2019, Acta Endocrinologica Foundation. All rights reserved.


Anahtar Kelimeler

Adipokines, Chemerin, Diabetes Mellitus, Irisin


Acta Endocrinologica

WoS Q Değeri


Scopus Q Değeri







Balaban, Y. A., Yilmaz, N., Kalayci, M., Unal, M., & Turhan, T. (2019). IRISIN AND CHEMERIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Acta Endocrinologica (Bucharest), 15(4), 442.